The degree of spreading of Hodgkin's lymphoma (HL) is usually estimated according to An Arbor classification system and its modifications. Some laboratory parameters are routinely determined at diagnosis and their abnormal values tries to correlate with disease activity or extension. OBJECTIVES of the research were to identify relationship between common laboratory parameters used in patients with HL, with focus on Serum copper level (SCL) and the degree of spreading of disease expressed through clinical stage (CS). Research was carried out through retrospective analysis of medical records of 47 previously untreated HL patients. The study evaluated descriptive statistical parameters, mean, median, standard deviation, minimum and maximum values, ANOVA, X2 test, Man-Whitney test and Spearman's correlation. Statistical analyzes performed using SPSS statistical software v.13.0. Results have presented in form of tables and graphs. Significance level less than 0.05 considered significant. The results of study shown good sensitivity of SCL (61,9%), and very high specificity (95,3%) in diagnosis of HL. PPV of SCL in our study was 92,9%, and NPV-- 71,9%. On the other hand, the results did not confirm correlation between serum copper level and spreading of disease. Serum levels of albumin, gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) showed good correlation with clinical stage. Our results did not confirm significance of serum copper level in term of staging of HL. Sensitivity and significance of serum copper in HL was very good and real prognostic impact of its elevated level in these patients should be assessed, and the research conducted on a larger number of subjects. Key words: Hodgkin's

Background/Objectives: Elevated lipoprotein(a) [Lp(a)] is an independent causal risk factor for atherosclerotic cardiovascular disease and may contribute to increased coronary complexity and adverse outcomes after acute myocardial infarction (AMI). Data regarding its prognostic significance in Southeastern Europe remains limited. This study aimed to evaluate the association between elevated Lp(a) levels, coronary artery disease severity, and major adverse cardiovascular events (MACE) at 1 and 6 months after AMI. Methods: This prospective study included 150 consecutive patients with STEMI and NSTEMI enrolled between December 2024 and August 2025. MACE was defined as a composite of overall cardiac death, recurrent myocardial infarction, cerebrovascular insult, heart failure with reduced ejection fraction occurrence, and new revascularization, either PCI or CABG. Results: Patients with elevated Lp(a) had significantly greater coronary disease burden, reflected by higher mean SYNTAX scores (17.3 ± 7.0 vs. 13.8 ± 7.0; p = 0.011) and a greater proportion of intermediate- and high-risk SYNTAX classifications (p = 0.016). Although the number of diseased vessels did not differ significantly, three-vessel disease was more frequent in the elevated Lp(a) group. At 1-month follow-up, overall MACE incidence was numerically higher but not statistically significant between groups. At 6 months, heart failure with reduced ejection fraction was significantly increased in patients with elevated Lp(a) (27.7% vs. 12.2%; p = 0.027). Binary logistic regression demonstrated that elevated Lp(a) independently predicted 6-month MACE (OR 2.768, p = 0.011, 95% CI 1.262–6.072), but not 1-month outcomes. Conclusions: Elevated Lp(a) is associated with increased coronary artery disease severity and higher mid-term MACE risk after AMI.